Observational studyEinstein (Sao Paulo, Brazil)2025
A prospective and longitudinal cohort study assessing postacute sequelae of SARS-CoV-2 infection in patients with cancer.
Observational study in Einstein (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePost-COVID symptoms are frequent and can be debilitating, particularly in individuals with cancer. However, their impact on this population remains unclear. This study aimed to prospectively assess the symptoms and impairments following COVID-19 hospitalization in patients with cancer, focusing on fatigue, nutritional status, speech and swallowing, anxiety, depression, and posttraumatic stress disorder symptoms.
methodsThis prospective observational cohort study included cancer survivors hospitalized with COVID-19 between June and December 2020. We assessed symptoms and impairments related to fatigue, independence in activities of daily living, speech and swallowing, voice, nutritional risk, anxiety/depression, and posttraumatic stress disorder. The participants were assessed at discharge and after 1, 3, 6 and 12 months.
resultsA total of 51 participants were included in the study. At the time of discharge, 98% had at least one of the following impairments: fatigue (68.6%), anxiety/depressive symptoms (17.7%), voice and speech impairments (19.6%), dysphagia (21.6%), or nutritional risk (45.1%). By one year, impairments persisted in 66% of the sample: fatigue (34.2%), anxiety/depressive symptoms (19.5%), voice and speech impairments (12.2%), and dysphagia (17.1%), with no participants remaining at nutritional risk. The participants reported no significant limitations in their daily living activities.
conclusionCancer survivors hospitalized for COVID-19 presented with high levels of fatigue, nutritional risk, anxiety/depression, and posttraumatic stress disorder symptoms at discharge, with improvements in fatigue and nutrition after one year.
background■ High fatigue and nutritional risk at discharge improved over one year in cancer survivors.
background■ Psychological symptoms, such as anxiety, depression, and posttraumatic stress disorder, remained prevalent for one year.
background■ 66% of patients had lasting symptoms or impairments after 12 months of follow-up.
background■ Nutritional risk was resolved in the following year. A prospective study of 51 cancer survivors hospitalized for COVID-19 revealed high initial levels of fatigue, nutritional risk, anxiety/depression, and posttraumatic stress disorder symptoms, with impairments persisting in 66% of patients after 1 year. Nutritional risk was resolved; however, psychological, and physical symptoms remained prevalent and required continuous care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.